ArticleScientific reports2025
Probiotics containing Lactobacillus are promising candidates for cisplatin-induced cardiotoxicity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the effects of the mixture of probiotics Lactobacillus (Lactobacillus rhamnosus, Lactobacillus fermentum, and Lactobacillus brevis) against cardiotoxicity induced by cisplatin (CP) in rats by monitoring markers of oxidative stress, inflammation, and apoptosis in cardiac tissue. For this study, 28 male rats were divided into four groups as follows: Control, CP, Lactobacillus + CP, and Lactobacillus. Experimental cardiotoxicity was induced by CP. The activity of cardiac enzymes in serum and indicators of oxidative stress and nitric oxide (NO) in heart tissues were measured using biochemical methods. Inflammation, apoptosis, and DNA damage were also assessed in cardiac tissue by immunohistochemistry and immunofluorescence. CP administration caused a significant increases (p < 0.01) in malondialdehyde (1.53 ± 0.21), NO (77.83 ± 4.26), and 8-hydroxydeoxyguanosine (8-OHdG) (80.50 ± 1.64) levels as well as marked decreases (p < 0.01) in the activity of superoxide dismutase (0.93 ± 0.15) and the level of glutathione (1.87 ± 0.20) in the CP group compared with those in the control group (0.88 ± 0.19, 53.67 ± 5.32, 21.67 ± 0.81, 1.39 ± 0.29, 2.64 ± 0.28, respectively). This imbalance in the oxidant/antioxidant system was accompanied by increased expression of tumor necrosis factor-alpha (TNF-α), Bcl-2-associated X protein (Bax), and caspase-3. CP also caused degenerative and necrotic changes in cardiac tissues and increased cardiac biomarkers, such as serum creatine kinase, creatine kinase myocardial band, lactate dehydrogenase, and troponin I. In contrast, the Lactobacillus probiotic administration significantly reduced (p < 0.01) malondialdehyde (1.04 ± 0.21) and NO (56.33 ± 5.39) levels in the Lactobacillus + CP group compared with those in the CP group, and significantly increased (p < 0.01) GSH levels (2.33 ± 0.14) in the Lactobacillus + CP group compared with that in the CP group. Lactobacillus probiotic also decreased TNF-α, 8-OHdG, Bax, and caspase-3 expression, and increased the expression of B-cell lymphoma 2. This enhanced the histopathology of the heart and positively affected cardiac biomarkers. In conclusion, the probiotic Lactobacillus reversed cardiotoxicity by suppressing oxidative stress, attenuating the inflammatory process, and improving the proteins that regulate apoptosis. Our findings support the use of probiotics to treat cardiotoxicity resulting from cancer therapy with CP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.